Last Updated: June 22, 2026

Claims for Patent: 10,744,139

✉ Email this page to a colleague

Summary for Patent: 10,744,139

Title:	Inhibitors of fibroblast growth factor receptor and use thereof
Abstract:	Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R1, R2, R3, R4, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.
Inventor(s):	Frank Wu
Assignee:	Transthera Sciences Nanjing Inc
Application Number:	US16/328,817

Details for Patent 10,744,139

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	August 27, 2009	⤷ Start Trial	2037-08-10
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	June 15, 2011	⤷ Start Trial	2037-08-10
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	July 13, 2011	⤷ Start Trial	2037-08-10
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	March 25, 2014	⤷ Start Trial	2037-08-10
Zenpep, Llc	ZENPEP	pancrelipase	Capsule, Delayed Release	022210	October 27, 2023	⤷ Start Trial	2037-08-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,744,139

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2017317864	⤷ Start Trial
China	107793395	⤷ Start Trial
European Patent Office	3508482	⤷ Start Trial
Spain	2859637	⤷ Start Trial
Japan	2019529374	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.